人工肝支持系统联合中药治疗慢性重型肝炎临床研究  

Clinical study of combination therapy of artificial liver treatment and traditional Chinese medicine in patients with chronic severe hepatitis

作　　者：李芹[1] 林恢[1] 刘政芳[1] 陈丽芳[1] 潘晨[1] 张娟娟[1] 

机构地区：[1]福州市传染病医院中西医结合科,福建福州350025

出　　处：《中西医结合肝病杂志》2010年第1期12-14,共3页Chinese Journal of Integrated Traditional and Western Medicine on Liver Diseases

基　　金：福建省中医药科研课题(No.wzy0604)

摘　　要：目的:研究人工肝联合中药方重肝合剂治疗慢性重型肝炎(CSH)的疗效。方法:将90例早、中期CSH患者随机分为试验组与对照组,每组45例。对照组给予内科综合治疗及血浆置换,治疗组在对照组的基础上加用重肝合剂,比较两组患者在治疗第6周末的主要临床症状改善情况、肝功能、凝血功能、并发症的发生率、血浆置换次数及其疗效等情况。结果:治疗组症状改善优于对照组(P<0.05)。治疗组总有效率为82.22%;对照组总有效率为62.22%,两组总有效率比较差异有显著性意义(P<0.05)。两组患者总胆红素(TBil)水平均明显降低,与治疗前比较均有显著性意义(P<0.05)。治疗组进行血浆置换(3.1±1.5)次,对照组(5.8±1.6)次,两组比较差异有显著性意义(P<0.05)。结论:人工肝联合中药方重肝合剂治疗早、中期慢性重型肝炎可改善患者临床症状,促进胆红素的代谢,减少并发症的发生率,减少人工肝治疗次数,改善患者预后。Objective： To observe the effect of artificial liver treatment concomitant with Zhonggan decoction in the treatment of chronic severe hepatitis. Methods ： Based on randomization, 90 cases of the early stage and metaphase were divided into tentative group and control group： the control group was treated with conventional internal medicine therapy together with plasma exchange, while the tentative group was treated with additional traditional Chinese medicine Zhonggan decoction, besides the therapy for the control group. Two groups were 45 cases respectively. To analysis the period of the disappearance of the main clinical symptoms, the serum level of liver function and blood coagulation function, and the occurrence of complication. After therapy, we would compare the clinical effectiveness between two groups in terms of the above contents. Results： Symptoms were alleviated more greatly in the patients of the treatment group than that of the control group （ P 〈 0. 05 ） . The total effectiveness rate in treatment group was 82. 22% , much higher than in control group （62. 22% , P 〈0. 05） . The level of TBil in both groups had been greatly decreased after treatment, with a significant difference （ P 〈 0. 05 ） . The frequency of plasma exchange was （3.1 ± 1.5 ） times in the treatment group, and （5.8 ± 1.6） times in the control group, with a significant difference between the two groups （P 〈 0. 01 ） . Conclusion： The combination therapy of artificial liver treatment and traditional Chinese medicine can relieve symptoms, enhance metabolism of TBil and reduce the frequency of plasma exchange. It achieves good therapeutic efficacy in the treatment of chronic severe hepatitis in the early or middle stage.

关 键 词：肝炎 慢性重型 中药 人工肝支持系统 临床研究 

分 类 号：R575.1[医药卫生—消化系统]